Understanding Potency Levels in Topical Corticosteroids
Potency varies wildly across the topical steroid class, and most people who prescribe them don't really track it past a handful of first-line options. When I started seeing skin cases more regularly back in residency, I learned the hard way that a patient with a thick plaque on their shin was going to need something stronger than what we'd reach for on their face. The reason charts exist at all is because hydrocortisone 1% cream won't do much for psoriasis on the palms, but applying clobetasol propionate 0.05% there would be overkill in every sense except the therapeutic one. Getting the match right between lesion and strength is where the actual clinical work happens, not in memorizing the whole list.
How I Use a Topical Steroid Strength Chart
I keep a printed reference somewhere nearby rather than trying to hold the hierarchy in my head. It's faster to glance at one than risk underdosing a patient who's already frustrated. The chart breaks down into four main groups, starting with the super-high potency end and moving down to the weakest. Group 1 covers clobetasol propionate 0.05%, betamethasone dipropionate 0.05%, and diflorasone diacetate 0.05%. These are the ones you reserve for recalcitrant plaques, scalp psoriasis, or situations where a short burst is acceptable. Anything applied under occlusion in this tier pushes systemic absorption through the roof, and I've seen patients develop hypothalamic-pituitary-adrenal axis suppression from prolonged use without realizing what was happening. Group 2 includes mometasone furoate 0.1%, halobetasol 0.05%, and fluocinonide 0.05%. This bracket is what most dermatologists reach for on the body when Group 1 is too much but Group 3 won't cut it. Mometasone sits in that middle ground where it's strong enough for moderate eczema flares but less likely to cause skin atrophy on thinner areas if you're judicious about duration.
Group 3 is where fluticasone propionate 0.05%, triamcinolone acetonide 0.1%, and betamethasone valerate 0.1% live. These are the workhorses. I see triamcinolone used constantly for inflammatory dermatoses across most body surfaces except the face and intertriginous zones. The concentration matters more than people realize — 0.025% triamcinolone is a different animal from 0.1%, and mixing up the two is one of the most common prescribing errors I encounter. Group 4 starts at hydrocortisone and drops off toward the bottom with the so-called baby-safe categories. Hydrocortisone 2.5% is actually a prescription-grade option in some markets and is strong enough to be useful for children in small amounts. Anything below that tends to be cosmetic-grade OTC in most regions and provides marginal benefit over simple emollients for true inflammatory conditions.
Get the Full Details
Topical Steroid Strength Chart
A proper chart organizes by group first, then lists the available vehicle options, because the same molecule in an ointment versus a cream versus a solution can behave differently on the skin. Clobetasol in an ointment base penetrates better than in cream form, which means switching vehicles can effectively change potency without changing the molecule. That detail doesn't appear on most simplified references, and it matters when a patient isn't responding to what should be adequate therapy. Vehicle choice accounts for about as much variability as concentration itself. Ointments are the most potent delivery system for a given molecule. Creams sit in the middle. Lotions and solutions tend to absorb faster but don't maintain as much occlusion on the skin surface, which can reduce both efficacy and the risk profile for thinner areas. I had a patient who kept failing treatment on her forearms because the lotion formulation evaporated before delivering meaningful dose, and switching to an ointment resolved it within a week.
Practical Pitfalls and What Charts Don't Tell You
Charts show potency hierarchies, but they don't capture that facial skin absorbs roughly 40 times more than forearm skin, and scalp absorption is even higher due to follicular density and the occlusive nature of hair. Applying a Group 2 steroid to the face isn't just a mild misstep — it carries real risk of steroid-induced rosacea, perioral dermatitis, and visible telangiectasia within weeks of regular use. Another thing no chart emphasizes is duration. A Group 1 steroid used for five days on a small plaque is fine. The same steroid used for six weeks across a large area is where you start worrying about adrenal suppression, skin atrophy, and telangiectasia. The British Association of Dermatologists guidelines recommend limiting super-high potency steroids to a maximum of two weeks unless there's clear monitoring in place, and even then, I'd be cautious about extending beyond that. Body surface area matters enormously. A patient applying clobetasol over their entire back twice daily is absorbing significantly more drug than someone applying it to a single quarter-sized patch. I once calculated the approximate systemic exposure for a patient using Group 1 steroid across 20% of body surface area and the numbers were comparable to oral prednisone in terms of HPA axis impact. That's not theoretical. It happened in my clinic.
When a Chart Isn't Enough
Some conditions respond better to non-steroid options regardless of the potency tier. The calcineurin inhibitors like tacrolimus and pimecrolimus occupy a useful space for facial and intertriginous eczema precisely because they don't cause atrophy. They burn on application for the first few days, which puts some patients off, but after that the side effect profile is dramatically better for long-term maintenance on thin skin. PDE4 inhibitors like crisaborole offer another non-steroid path for mild-to-moderate atopic dermatitis, though the cost and insurance coverage in the US remains a barrier for many patients. I use these when I want to avoid steroids altogether on a patient who has a history of skin thinning from previous treatments. There's also the issue of rebound. Stopping a high-potency steroid abruptly after prolonged use on a condition that was partially controlled can produce a flare that looks worse than the original presentation. This is one reason I taper rather than quit cold turkey when patients have been on medium-to-high potency steroids for more than two to three weeks. A simple taper schedule — alternate days for a week, then every other day for another week — reduces the likelihood of a severe rebound event without requiring ongoing potent steroid exposure.
Bottom Line on Using These References
The chart is a starting point, not a decision framework. The actual selection depends on the diagnosis, the anatomical site, the patient's age, the body surface area involved, the duration of treatment planned, and whether the patient has a history of skin atrophy or steroid complications. I've seen patients lose pigment on treated areas, develop striae from inappropriate use on the abdomen, and experience significant HPA suppression from misuse. None of that shows up on a potency chart. Keep the chart handy for quick reference on molecule-to-group mapping. Trust your clinical judgment for everything else. The strongest steroid isn't always the right one, and the weakest steroid that controls the condition is usually the best choice for long-term management. That principle is worth more than any hierarchy you can print out.
